Aladdin

Bezuclastinib (CGT9486) is a novel, potent and highly selective tyrosine kinase and c-kit D816V inhibitor for the study of advanced mastocytosis.

Bezuclastinib (CGT9486) is a novel, potent and highly selective tyrosine kinase and c-kit D816V inhibitor for the study of advanced mastocytosis.

Bezuclastinib (CGT9486) is a novel, potent and highly selective tyrosine kinase and c-kit D816V inhibitor for the study of advanced mastocytosis.

Bezuclastinib (CGT9486) is a novel, potent and highly selective tyrosine kinase and c-kit D816V inhibitor for the study of advanced mastocytosis.

Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the

Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the

Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the

BAY-1797 is an orally active and selective P2X4 antagonist (IC50: 211 nM against human P2X4) with anti-nociceptive and anti-inflammatory effects. BAY-1797 displays no or very weak activity on the other P2X ion channels.Target activityhuman P2X7:10.6

BAY-1797 is an orally active and selective P2X4 antagonist (IC50: 211 nM against human P2X4) with anti-nociceptive and anti-inflammatory effects. BAY-1797 displays no or very weak activity on the other P2X ion channels.Target activityhuman P2X7:10.6

BAY-1797 is an orally active and selective P2X4 antagonist (IC50: 211 nM against human P2X4) with anti-nociceptive and anti-inflammatory effects. BAY-1797 displays no or very weak activity on the other P2X ion channels.Target activityhuman P2X7:10.6

BAY-1797 is an orally active and selective P2X4 antagonist (IC50: 211 nM against human P2X4) with anti-nociceptive and anti-inflammatory effects. BAY-1797 displays no or very weak activity on the other P2X ion channels.Target activityhuman P2X7:10.6

Bag-2 is a Novel potent, non-peptidic bombesin receptor subtype-3 (BRS-3) agonist.